Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 4/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569048 | 0.89 | CACNA1B (0.41) | CACNA1FCACNA1DCACNA1SCACNA1CGAA | |
| SCHEMBL5563397 | 0.81 | NPY5R (0.44) | CACNA1BMAPTADRA1DADRA1AADRA1B | |
| SCHEMBL20328325 | 0.81 | CACNA1F (0.40) | XBP1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5568219 | 0.81 | CACNA1B (0.43) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1B | |
| SCHEMBL8302877 | 0.80 | CACNA1F (0.47) | XBP1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5568116 | 0.79 | CACNA1F (0.40) | XBP1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL20328168 | 0.78 | CACNA1F (0.40) | XBP1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5563157 | 0.77 | HTT (0.39) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1B | |
| SCHEMBL20328142 | 0.76 | CACNA1F (0.36) | XBP1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5563888 | 0.76 | CACNA1F (0.38) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | disclosed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | CACNA1E, CACNA1C, CACNA1S | XBP1 2231/4885CACNA1F 6/4885CACNA1D 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.